1595 related articles for article (PubMed ID: 21436454)
1. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
Beatty GL; Chiorean EG; Fishman MP; Saboury B; Teitelbaum UR; Sun W; Huhn RD; Song W; Li D; Sharp LL; Torigian DA; O'Dwyer PJ; Vonderheide RH
Science; 2011 Mar; 331(6024):1612-6. PubMed ID: 21436454
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.
Beatty GL; Torigian DA; Chiorean EG; Saboury B; Brothers A; Alavi A; Troxel AB; Sun W; Teitelbaum UR; Vonderheide RH; O'Dwyer PJ
Clin Cancer Res; 2013 Nov; 19(22):6286-95. PubMed ID: 23983255
[TBL] [Abstract][Full Text] [Related]
3. Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages.
Beatty GL; Winograd R; Evans RA; Long KB; Luque SL; Lee JW; Clendenin C; Gladney WL; Knoblock DM; Guirnalda PD; Vonderheide RH
Gastroenterology; 2015 Jul; 149(1):201-10. PubMed ID: 25888329
[TBL] [Abstract][Full Text] [Related]
4. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
Morrison AH; Diamond MS; Hay CA; Byrne KT; Vonderheide RH
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8022-8031. PubMed ID: 32213589
[TBL] [Abstract][Full Text] [Related]
5. CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.
Byrne KT; Vonderheide RH
Cell Rep; 2016 Jun; 15(12):2719-32. PubMed ID: 27292635
[TBL] [Abstract][Full Text] [Related]
6. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.
Neesse A; Frese KK; Bapiro TE; Nakagawa T; Sternlicht MD; Seeley TW; Pilarsky C; Jodrell DI; Spong SM; Tuveson DA
Proc Natl Acad Sci U S A; 2013 Jul; 110(30):12325-30. PubMed ID: 23836645
[TBL] [Abstract][Full Text] [Related]
7. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.
Winograd R; Byrne KT; Evans RA; Odorizzi PM; Meyer AR; Bajor DL; Clendenin C; Stanger BZ; Furth EE; Wherry EJ; Vonderheide RH
Cancer Immunol Res; 2015 Apr; 3(4):399-411. PubMed ID: 25678581
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.
Bunt SK; Mohr AM; Bailey JM; Grandgenett PM; Hollingsworth MA
Cancer Immunol Immunother; 2013 Feb; 62(2):225-36. PubMed ID: 22864396
[TBL] [Abstract][Full Text] [Related]
9. Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy.
Baumann D; Hägele T; Mochayedi J; Drebant J; Vent C; Blobner S; Noll JH; Nickel I; Schumacher C; Boos SL; Daniel AS; Wendler S; Volkmar M; Strobel O; Offringa R
Nat Commun; 2020 May; 11(1):2176. PubMed ID: 32358491
[TBL] [Abstract][Full Text] [Related]
10. TNF blockade uncouples toxicity from antitumor efficacy induced with CD40 chemoimmunotherapy.
Stone ML; Lee J; Herrera VM; Graham K; Lee JW; Huffman A; Coho H; Tooker E; Myers MI; Giannone M; Li Y; Buckingham TH; Long KB; Beatty GL
JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34101617
[TBL] [Abstract][Full Text] [Related]
11. Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism.
Jiang H; Courau T; Borison J; Ritchie AJ; Mayer AT; Krummel MF; Collisson EA
Gastroenterology; 2022 Feb; 162(2):590-603.e14. PubMed ID: 34627860
[TBL] [Abstract][Full Text] [Related]
12. Harnessing immune responses in the tumor microenvironment: all signals needed.
Le DT; Jaffee EM
Clin Cancer Res; 2013 Nov; 19(22):6061-3. PubMed ID: 24097857
[TBL] [Abstract][Full Text] [Related]
13. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
Rajeshkumar NV; Rasheed ZA; García-García E; López-Ríos F; Fujiwara K; Matsui WH; Hidalgo M
Mol Cancer Ther; 2010 Sep; 9(9):2582-92. PubMed ID: 20660600
[TBL] [Abstract][Full Text] [Related]
14. Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer.
Halbrook CJ; Pontious C; Kovalenko I; Lapienyte L; Dreyer S; Lee HJ; Thurston G; Zhang Y; Lazarus J; Sajjakulnukit P; Hong HS; Kremer DM; Nelson BS; Kemp S; Zhang L; Chang D; Biankin A; Shi J; Frankel TL; Crawford HC; Morton JP; Pasca di Magliano M; Lyssiotis CA
Cell Metab; 2019 Jun; 29(6):1390-1399.e6. PubMed ID: 30827862
[TBL] [Abstract][Full Text] [Related]
15. T Cell-Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer.
Li D; Schaub N; Guerin TM; Bapiro TE; Richards FM; Chen V; Talsania K; Kumar P; Gilbert DJ; Schlomer JJ; Kim SJ; Sorber R; Teper Y; Bautista W; Palena C; Ock CY; Jodrell DI; Pate N; Mehta M; Zhao Y; Kozlov S; Rudloff U
Mol Cancer Ther; 2021 Oct; 20(10):1926-1940. PubMed ID: 34376576
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine resistance in pancreatic ductal adenocarcinoma.
Binenbaum Y; Na'ara S; Gil Z
Drug Resist Updat; 2015 Nov; 23():55-68. PubMed ID: 26690340
[TBL] [Abstract][Full Text] [Related]
17. C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer.
Sasaki K; Takano S; Tomizawa S; Miyahara Y; Furukawa K; Takayashiki T; Kuboki S; Takada M; Ohtsuka M
J Exp Clin Cancer Res; 2021 Jun; 40(1):212. PubMed ID: 34167573
[TBL] [Abstract][Full Text] [Related]
18. CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy.
Byrne KT; Leisenring NH; Bajor DL; Vonderheide RH
J Immunol; 2016 Jul; 197(1):179-87. PubMed ID: 27217585
[TBL] [Abstract][Full Text] [Related]
19. Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma.
Elahi-Gedwillo KY; Carlson M; Zettervall J; Provenzano PP
Cancer Res; 2019 Jan; 79(2):372-386. PubMed ID: 30401713
[TBL] [Abstract][Full Text] [Related]
20. Codelivery Nanosystem Targeting the Deep Microenvironment of Pancreatic Cancer.
Chen X; Zhou W; Liang C; Shi S; Yu X; Chen Q; Sun T; Lu Y; Zhang Y; Guo Q; Li C; Zhang Y; Jiang C
Nano Lett; 2019 Jun; 19(6):3527-3534. PubMed ID: 31058513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
